Award type :
Bridging Award
Bridging Award
Product type :
Vaccines
Vaccines
Award year :
2021
2021
Project start date :
2021/ 06 / 22
2021/ 06 / 22
Project end date :
-
-
Project duration (months) :
45
45
Development stage :
Phase 3
Phase 3
Target disease :
Typhoid
Typhoid
Region served :
World
World
Recipient organization / Country of funding recipient organization :
EuBiologics / Republic of Korea
EuBiologics / Republic of Korea
Collaborator(s) / Country :
Program for Appropriate Technology in Health (PATH) / USA
Program for Appropriate Technology in Health (PATH) / USA
Funding amount(KRW) :
4,000,000,000
4,000,000,000
Subsequent Project :
🔗Immune persistence assessment of Typhoid Conjugate Vaccine
🔗Immune persistence assessment of Typhoid Conjugate Vaccine
EuTCV, a typhoid conjugate vaccine designed for co-administration with measles-rubella and yellow fever vaccines in both single- and multi-dose presentations, was developed to enhance compatibility with EPI schedules. Phase 3 trials in Kenya and Senegal demonstrated immunological non-inferiority to the reference vaccine Typbar TCV, with acceptable safety and reactogenicity across infants, children, and adults. A three-year immune persistence follow-up study is ongoing in a subpopulation in Senegal to assess the durability of vaccine-induced protection.